SI2324008T1 - 3,4-diarilpirazoli kot protein-kinazni inhibitorji - Google Patents
3,4-diarilpirazoli kot protein-kinazni inhibitorjiInfo
- Publication number
- SI2324008T1 SI2324008T1 SI200930286T SI200930286T SI2324008T1 SI 2324008 T1 SI2324008 T1 SI 2324008T1 SI 200930286 T SI200930286 T SI 200930286T SI 200930286 T SI200930286 T SI 200930286T SI 2324008 T1 SI2324008 T1 SI 2324008T1
- Authority
- SI
- Slovenia
- Prior art keywords
- protein kinase
- diarylpyrazoles
- kinase inhibitors
- cancer
- therapy
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08161076 | 2008-07-24 | ||
| EP09780990A EP2324008B1 (en) | 2008-07-24 | 2009-07-23 | 3,4-diarylpyrazoles as protein kinase inhibitors |
| PCT/EP2009/059506 WO2010010154A1 (en) | 2008-07-24 | 2009-07-23 | 3,4-diarylpyrazoles as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2324008T1 true SI2324008T1 (sl) | 2012-08-31 |
Family
ID=41059486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200930286T SI2324008T1 (sl) | 2008-07-24 | 2009-07-23 | 3,4-diarilpirazoli kot protein-kinazni inhibitorji |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8541575B2 (enExample) |
| EP (1) | EP2324008B1 (enExample) |
| JP (1) | JP5385382B2 (enExample) |
| CN (1) | CN102105459B (enExample) |
| AT (1) | ATE557015T1 (enExample) |
| AU (1) | AU2009273197B2 (enExample) |
| BR (1) | BRPI0916356B1 (enExample) |
| CA (1) | CA2731146C (enExample) |
| CL (1) | CL2011000124A1 (enExample) |
| CY (1) | CY1117667T1 (enExample) |
| DK (1) | DK2324008T3 (enExample) |
| EA (1) | EA019722B1 (enExample) |
| ES (1) | ES2386408T3 (enExample) |
| HR (1) | HRP20120577T1 (enExample) |
| MX (1) | MX2011000738A (enExample) |
| PL (1) | PL2324008T3 (enExample) |
| PT (1) | PT2324008E (enExample) |
| SI (1) | SI2324008T1 (enExample) |
| WO (1) | WO2010010154A1 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20090837A1 (es) | 2007-07-02 | 2009-07-24 | Boehringer Ingelheim Int | Nuevos compuestos quimicos |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| JP5385382B2 (ja) * | 2008-07-24 | 2014-01-08 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | プロテインキナーゼ阻害剤としての３，４−ジアリールピラゾール |
| EA201100564A1 (ru) | 2008-09-29 | 2011-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Антипролиферативные соединения |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| WO2011092088A1 (en) | 2010-01-27 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
| JP5871896B2 (ja) | 2010-03-26 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂ−ｒａｆキナーゼインヒビター |
| WO2011117382A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
| AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| KR20130048293A (ko) * | 2010-06-25 | 2013-05-09 | 노파르티스 아게 | 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물 |
| JP5938038B2 (ja) * | 2010-08-03 | 2016-06-22 | ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ | ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用 |
| TWI480276B (zh) * | 2010-08-27 | 2015-04-11 | Irm Llc | 作為蛋白質激酶抑制劑之化合物及組合物 |
| US8710055B2 (en) * | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| SG192126A1 (en) * | 2011-01-25 | 2013-09-30 | Univ Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
| BR112013021537B1 (pt) * | 2011-02-24 | 2021-08-10 | Nerviano Medical Sciences S.R.L. | Derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase |
| KR101298651B1 (ko) * | 2011-03-16 | 2013-08-21 | 연세대학교 산학협력단 | 효능이 강화된 혈관신생 억제용 약제학적 조성물 |
| WO2013050434A1 (en) | 2011-10-06 | 2013-04-11 | Bayer Intellectual Property Gmbh | Heterocyclylpyri(mi)dinylpyrazole |
| CA2851142A1 (en) | 2011-10-06 | 2013-04-11 | Bayer Intellectual Property Gmbh | Heterocyclylpyri (mi) dinylpyrazole as fungicidals |
| WO2013070996A1 (en) | 2011-11-11 | 2013-05-16 | Novartis Ag | Method of treating a proliferative disease |
| WO2013078264A1 (en) | 2011-11-23 | 2013-05-30 | Novartis Ag | Pharmaceutical formulations |
| KR101668574B1 (ko) | 2012-11-02 | 2016-10-24 | 화이자 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
| JP6347793B2 (ja) | 2013-01-16 | 2018-06-27 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| ES2918924T3 (es) | 2015-04-01 | 2022-07-21 | Rigel Pharmaceuticals Inc | Inhibidores de TGF-beta |
| MY198809A (en) * | 2015-08-03 | 2023-09-28 | Glenmark Pharmaceuticals Sa | Novel compounds as ror gamma modulators |
| CN114685516A (zh) | 2015-09-16 | 2022-07-01 | 洛克索肿瘤学股份有限公司 | 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物 |
| PT3390395T (pt) * | 2015-12-16 | 2020-11-03 | Loxo Oncology Inc | Compostos úteis como inibidores de quinase |
| UA125436C2 (uk) | 2016-06-03 | 2022-03-09 | Еррей Біофарма, Інк. | Фармацевтичні комбінації |
| KR102341660B1 (ko) | 2016-09-19 | 2021-12-23 | 노파르티스 아게 | Raf 억제제 및 erk 억제제를 포함하는 치료적 조합 |
| CN106883266B (zh) * | 2017-01-23 | 2020-03-17 | 江苏七洲绿色化工股份有限公司 | 一种1-(4-氯苯基)-2-环丙基-1-丙酮的制备方法及其中间体 |
| ES2952265T3 (es) | 2017-05-02 | 2023-10-30 | Novartis Ag | Terapia combinada que comprende un inhibidor de Raf y trametinib |
| WO2019081485A1 (de) | 2017-10-26 | 2019-05-02 | Bayer Cropscience Aktiengesellschaft | Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| WO2019081477A1 (de) | 2017-10-26 | 2019-05-02 | Bayer Cropscience Aktiengesellschaft | Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| JP7186874B2 (ja) * | 2018-10-26 | 2022-12-09 | アーリーン ファーマシューティカルズ エルエルシー | ピラゾリル化合物およびその使用方法 |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| EP3969449B1 (en) | 2019-05-13 | 2025-02-12 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| BR112021020565A2 (pt) | 2019-06-03 | 2021-12-21 | Bayer Ag | Ácidos 1-fenil-5-azinil pirazolil-3-oxialquílicos e seu uso para o controle do crescimento indesejado de plantas |
| BR112022002698A2 (pt) | 2019-08-14 | 2022-07-19 | Incyte Corp | Compostos de imidazolil pirimidinilamina como inibidores de cdk2 |
| AU2020364007A1 (en) | 2019-10-11 | 2022-04-28 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| KR102323820B1 (ko) * | 2019-10-31 | 2021-11-08 | 한국화학연구원 | 돌연변이형 idh 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CN112979613B (zh) * | 2019-12-16 | 2022-04-26 | 四川大学华西医院 | 2-(1h-吡唑-3-基)吡啶衍生物及其制备方法和用途 |
| JP7631346B2 (ja) | 2019-12-19 | 2025-02-18 | バイエル・アクチエンゲゼルシヤフト | １，５－ジフェニルピラゾリル－３－オキシアルキル酸及び１－フェニル－５－チエニルピラゾリル－３－オキシアルキル酸並びに望ましくない植物の生長を制御するためのそれらの使用 |
| WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| EP4097087B1 (de) | 2020-01-31 | 2024-07-31 | Bayer Aktiengesellschaft | [(1,4,5-trisubstituierte-1h-pyrazol-3-yl)sulfanyl]essigsäure derivate sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| WO2021202900A1 (en) * | 2020-04-02 | 2021-10-07 | Plexxikon Inc. | 1,6-naphthyridine compounds and methods for csk modulation and indications therefor |
| WO2021219527A1 (de) | 2020-04-29 | 2021-11-04 | Bayer Aktiengesellschaft | 1-pyrazinylpyrazolyl-3-oxyalkylsäuren sowie deren derivate und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums |
| WO2021250521A1 (en) | 2020-06-09 | 2021-12-16 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
| AU2021367046A1 (en) | 2020-10-23 | 2023-06-08 | Bayer Aktiengesellschaft | 1-(pyridyl)-5-azinylpyrazole derivatives, and their use for control of undesired plant growth |
| TW202233607A (zh) * | 2020-10-30 | 2022-09-01 | 瑞士商諾華公司 | Ｋｒａｓ ｇ１２ｃ抑制劑化合物之新結晶形式 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| MX2023015094A (es) | 2021-06-25 | 2024-01-18 | Bayer Ag | Acidos de 1h-pirazol-3-il)oxi-2-alcoxi-alquilo 1,4,5-trisustituidos y derivados alquilicos de acido, sus sales y su uso como activos herbicidas. |
| US20250051300A1 (en) * | 2021-11-19 | 2025-02-13 | The Board Of Trustees Of The University Of Illinois | Gram-negative specific antibiotics sparing effect on gut microbiome |
| AU2022400175A1 (en) | 2021-12-01 | 2024-07-18 | Bayer Aktiengesellschaft | (1,4,5-trisubstituted-1h-pyrazole-3-yl)oxy-2-alkoxythio alkyl acids and derivatives thereof, their salts and their use as herbicidal active agents |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US12331026B2 (en) | 2022-03-28 | 2025-06-17 | Nikang Therapeutics, Inc. | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2024078871A1 (de) | 2022-10-14 | 2024-04-18 | Bayer Aktiengesellschaft | 1-pyridyl-5-phenylpyrazolyl-3-oxy- und -3-thioalkylsäuren und derivate und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| NZ501112A (en) | 1997-05-22 | 2002-10-25 | G | Substituted pyrazoles as p38 kinase inhibitors |
| DE60222804T2 (de) | 2001-12-21 | 2008-07-03 | Vernalis (Cambridge) Ltd., Abington | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
| RU2006128788A (ru) * | 2004-01-09 | 2008-02-20 | Новартис АГ (CH) | Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов |
| JP2009506040A (ja) | 2005-08-26 | 2009-02-12 | スミスクライン・ビーチャム・コーポレイション | オーロラキナーゼのピリミジニル−ピラゾール阻害剤 |
| WO2007105058A2 (en) * | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
| US8202876B2 (en) * | 2006-10-02 | 2012-06-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP5385382B2 (ja) * | 2008-07-24 | 2014-01-08 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | プロテインキナーゼ阻害剤としての３，４−ジアリールピラゾール |
| WO2011092088A1 (en) * | 2010-01-27 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
| JP5938038B2 (ja) | 2010-08-03 | 2016-06-22 | ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ | ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用 |
-
2009
- 2009-07-23 JP JP2011519176A patent/JP5385382B2/ja active Active
- 2009-07-23 HR HRP20120577AT patent/HRP20120577T1/hr unknown
- 2009-07-23 MX MX2011000738A patent/MX2011000738A/es active IP Right Grant
- 2009-07-23 AU AU2009273197A patent/AU2009273197B2/en active Active
- 2009-07-23 EA EA201170249A patent/EA019722B1/ru not_active IP Right Cessation
- 2009-07-23 AT AT09780990T patent/ATE557015T1/de active
- 2009-07-23 PL PL09780990T patent/PL2324008T3/pl unknown
- 2009-07-23 PT PT09780990T patent/PT2324008E/pt unknown
- 2009-07-23 ES ES09780990T patent/ES2386408T3/es active Active
- 2009-07-23 SI SI200930286T patent/SI2324008T1/sl unknown
- 2009-07-23 DK DK09780990.9T patent/DK2324008T3/da active
- 2009-07-23 EP EP09780990A patent/EP2324008B1/en active Active
- 2009-07-23 US US13/054,853 patent/US8541575B2/en active Active
- 2009-07-23 CA CA2731146A patent/CA2731146C/en active Active
- 2009-07-23 WO PCT/EP2009/059506 patent/WO2010010154A1/en not_active Ceased
- 2009-07-23 BR BRPI0916356-5A patent/BRPI0916356B1/pt active IP Right Grant
- 2009-07-23 CN CN200980128629.1A patent/CN102105459B/zh active Active
-
2011
- 2011-01-20 CL CL2011000124A patent/CL2011000124A1/es unknown
-
2012
- 2012-07-13 CY CY20121100628T patent/CY1117667T1/el unknown
-
2013
- 2013-08-20 US US13/970,854 patent/US8946250B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5385382B2 (ja) | 2014-01-08 |
| PT2324008E (pt) | 2012-06-25 |
| CA2731146A1 (en) | 2010-01-28 |
| HRP20120577T1 (hr) | 2012-08-31 |
| PL2324008T3 (pl) | 2012-09-28 |
| CY1117667T1 (el) | 2017-05-17 |
| EA019722B1 (ru) | 2014-05-30 |
| MX2011000738A (es) | 2011-02-23 |
| ES2386408T3 (es) | 2012-08-20 |
| AU2009273197A1 (en) | 2010-01-28 |
| BRPI0916356B1 (pt) | 2022-08-23 |
| CA2731146C (en) | 2016-05-03 |
| BRPI0916356A2 (enExample) | 2018-08-21 |
| US20140005150A1 (en) | 2014-01-02 |
| US20110144068A1 (en) | 2011-06-16 |
| CN102105459B (zh) | 2014-09-10 |
| AU2009273197A2 (en) | 2011-03-10 |
| ATE557015T1 (de) | 2012-05-15 |
| CN102105459A (zh) | 2011-06-22 |
| HK1157337A1 (en) | 2012-06-29 |
| WO2010010154A1 (en) | 2010-01-28 |
| EA201170249A1 (ru) | 2011-10-31 |
| US8541575B2 (en) | 2013-09-24 |
| CL2011000124A1 (es) | 2011-05-06 |
| US8946250B2 (en) | 2015-02-03 |
| AU2009273197B2 (en) | 2014-01-16 |
| JP2011528698A (ja) | 2011-11-24 |
| EP2324008B1 (en) | 2012-05-09 |
| DK2324008T3 (da) | 2012-07-23 |
| EP2324008A1 (en) | 2011-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2324008T3 (pl) | 3,4-diarylopirazole jako inhibitory kinazy białkowej | |
| MX2009006613A (es) | Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa. | |
| WO2009071480A3 (en) | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors | |
| PH12013501594A1 (en) | Substituted indazole derivatives active as kinase inhibitors | |
| MX2009006401A (es) | Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer. | |
| TW200505924A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
| MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
| UA94097C2 (ru) | Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| BRPI0413427A (pt) | derivados de piridilpirrol ativos como inibidores da cinase | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| MX2009010059A (es) | Derivados de quinolina para el tratamiento de enfermedades inflamatorias. | |
| WO2009007749A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| MX2010003927A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b. | |
| BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
| UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
| TW200510385A (en) | Pyrrolo[3, 4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
| CU23596A3 (es) | Derivados de pirazol-quinazolina y proceso para su preparación | |
| UA100390C2 (en) | Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors | |
| CU20060152A7 (es) | Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa |